This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2013 Apr;37(2):113-6.

doi: 10.4093/dmj.2013.37.2.113.

Metformin and cancer in type 2 diabetes

Hyeong Kyu Park¹

Affiliations

PMID: 23641351
PMCID: PMC3638221
DOI: 10.4093/dmj.2013.37.2.113

Metformin and cancer in type 2 diabetes

Hyeong Kyu Park. Diabetes Metab J. 2013 Apr.

. 2013 Apr;37(2):113-6.

doi: 10.4093/dmj.2013.37.2.113.

Author

Hyeong Kyu Park¹

Affiliation

¹ Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.

PMID: 23641351
PMCID: PMC3638221
DOI: 10.4093/dmj.2013.37.2.113

No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1 — Fig. 1
Effects of metformin on cancer. Metformin inhibits hepatic gluconeogenesis and stimulates glucose uptake in peripheral tissue, thereby lowering circulating insulin levels, and indirectly reducing phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling. Metformin also activates AMP-activated protein kinase (AMPK) leading to inhibition of mTOR signaling and protein synthesis in cancer cells. Metformin may directly inhibit mTOR signaling [30-32]. IR/IGF-1R, insulin receptor/insulin-like growth factor-1 receptor.

See this image and copyright information in PMC

Similar articles

Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer: A retrospective study.
Wang SB, Lei KJ, Liu JP, Jia YM. Wang SB, et al. Medicine (Baltimore). 2017 Jul;96(29):e7605. doi: 10.1097/MD.0000000000007605. Medicine (Baltimore). 2017. PMID: 28723808 Free PMC article.
Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes.
Muszyńska-Ogłaza A, Zarzycka-Lindner G, Olejniczak H, Polaszewska-Muszyńska M, Junik R. Muszyńska-Ogłaza A, et al. Endokrynol Pol. 2017;68(6):652-658. doi: 10.5603/EP.a2017.0054. Epub 2017 Oct 12. Endokrynol Pol. 2017. PMID: 29022647
The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes.
Chung HH, Moon JS, Yoon JS, Lee HW, Won KC. Chung HH, et al. Diabetes Metab J. 2013 Apr;37(2):125-31. doi: 10.4093/dmj.2013.37.2.125. Epub 2013 Apr 16. Diabetes Metab J. 2013. PMID: 23641353 Free PMC article.
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.
Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Kip KE. Zhang ZJ, et al. Diabetes Care. 2011 Oct;34(10):2323-8. doi: 10.2337/dc11-0512. Diabetes Care. 2011. PMID: 21949223 Free PMC article. Review.
Clinical Implication of Metformin in Relation to Diabetes Mellitus and Ovarian Cancer.
Singh SK, Apata T, Singh S, McFadden M, Singh R. Singh SK, et al. Biomedicines. 2021 Aug 16;9(8):1020. doi: 10.3390/biomedicines9081020. Biomedicines. 2021. PMID: 34440224 Free PMC article. Review.

See all similar articles

Cited by

The association between metabolic health, obesity phenotype and the risk of breast cancer.
Park YM, White AJ, Nichols HB, O'Brien KM, Weinberg CR, Sandler DP. Park YM, et al. Int J Cancer. 2017 Jun 15;140(12):2657-2666. doi: 10.1002/ijc.30684. Epub 2017 Mar 28. Int J Cancer. 2017. PMID: 28268252 Free PMC article.
Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients.
De Monte A, Brunetti D, Cattin L, Lavanda F, Naibo E, Malagoli M, Stanta G, Bonin S. De Monte A, et al. Mol Clin Oncol. 2018 Mar;8(3):504-512. doi: 10.3892/mco.2018.1554. Epub 2018 Jan 11. Mol Clin Oncol. 2018. PMID: 29456855 Free PMC article.
Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
Chen CB, Eskin M, Eurich DT, Majumdar SR, Johnson JA. Chen CB, et al. BMC Cancer. 2018 Jan 10;18(1):65. doi: 10.1186/s12885-017-3934-9. BMC Cancer. 2018. PMID: 29320995 Free PMC article.
Insulin signaling regulates a functional interaction between adenomatous polyposis coli and cytoplasmic dynein.
Gao FJ, Shi L, Hines T, Hebbar S, Neufeld KL, Smith DS. Gao FJ, et al. Mol Biol Cell. 2017 Mar 1;28(5):587-599. doi: 10.1091/mbc.E16-07-0555. Epub 2017 Jan 5. Mol Biol Cell. 2017. PMID: 28057765 Free PMC article.
Metformin Promotes Apoptosis but Suppresses Autophagy in Glucose-Deprived H4IIE Hepatocellular Carcinoma Cells.
Park DB. Park DB. Diabetes Metab J. 2015 Dec;39(6):518-27. doi: 10.4093/dmj.2015.39.6.518. Diabetes Metab J. 2015. PMID: 26706918 Free PMC article.

See all "Cited by" articles

References

1. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103–1123. - PubMed
1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–2764. - PMC - PubMed
1. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23:967–981. - PMC - PubMed
1. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–1167. - PubMed
1. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, 3rd, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433–440. - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations